Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Federal Trade Commission
UBS
Harvard Business School
Cipla
Express Scripts
Fuji
Dow
Merck
Fish and Richardson

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,776,433

« Back to Dashboard

Summary for Patent: 5,776,433
Title: Flunisolide aerosol formulations
Abstract:Pharmaceutical aerosol formulations substantially free of chlorofluorocarbons and comprising a therapeutically effective amount of flunisolide in solution with ethanol and a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof are used for the treatment of bronchial asthma. The formulation may be delivered by a metered dose inhaler with a canister that is inert to flunisolide.
Inventor(s): Tzou; Tsi-Zong (Lake Elmo, MN), Schultz; Robert K. (Edina, MN), Ross; Danna L. (Pine Springs, MN)
Assignee: Minnesota Mining and Manufacturing Company (St. Paul, MN)
Application Number:08/456,029
Patent Claim Types:
see list of patent claims
Formulation; Compound; Use; Delivery;

Drugs Protected by US Patent 5,776,433

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,776,433

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 1098695 ➤ Subscribe
Australia 680967 ➤ Subscribe
Canada 2178473 ➤ Subscribe
Germany 69424181 ➤ Subscribe
Denmark 0735884 ➤ Subscribe
European Patent Office 0735884 ➤ Subscribe
Spain 2145254 ➤ Subscribe
Japan H09506896 ➤ Subscribe
Norway 313123 ➤ Subscribe
Norway 962585 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Merck
Citi
Daiichi Sankyo
US Army
Express Scripts
Chubb
Teva
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot